-
-
-
-
-
-
-
bluebird bio (BLUE) to Sell Priority Review Voucher, if Granted, for $103M
-
-
-
-
-
-
-
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History
-
-
-
-
-
-
-
bluebird bio (BLUE) Announces FDA AdCom Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
-
-
-
-
-
-
-
bluebird bio (BLUE) Initiates Restructuring to Reduce Operating Expenses
-
-
-
-
-
-
-
bluebird bio (BLUE) Granted FDA Priority Review of Biologics License Application for eli-cel Gene Therapy
-
-
-
-
-
-
-
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
-
-
-
-
-
-
-
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

